Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Blood (2025) 146 (22): 2681–2695.

https://doi.org/10.1182/blood.2024027692

Published: 2025

Includes: Supplemental data

Journal Articles

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2025-3533

Published: 2025

Journal Articles

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Feng Zhu, Yile Zhou, Yi Zhang, Liping Mao, Yinjun Lou, Yu Zhu, Zheng Ge, Zhiyong Zeng, Fengbo Jin, Tingting Liu, Haitao Xu, Yue Yao, Quanyi Lu, Jianxin Guo, Hongyan Tong, Huafeng Wang, Jie Jin

Blood (2025) 146 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2025-1728

Published: 2025

Journal Articles

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Lixia Sheng, Wen Lei, Duo Wu, Yi Zhang, Yanli Lai, Shuyan Wang, Duobing Zou, Ping Zhang, Kaihong Xu, Shanhao Tang, Huijie Hu, Tongyu Li, Qitian Mu, Xiaofei Ye, Hui Liu, Wenbin Qian, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2025-1929

Published: 2025

Journal Articles

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Kaito Harada, Dandan Zhao, Miso Park, Fang Chen, Yongfang Xu, Yi Zhang, Yile Zhou, Bea Parcutela, Yead Jewel, Ashlie Munoz, Idoroenyi Amanam, Le Xuan Truong Nguyen, Jianjun Chen, Lucy Ghoda, Stephen Forman, John Williams, Bin Zhang, Guido Marcucci

Blood (2025) 146 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2025-2340

Published: 2025

Journal Articles

Apolipoproteins from the microenvironment promote aggressive myeloid leukemia progression

Christina Kaszuba, Sonali Sharma, Benjamin Rodems, Edgardo Franco, Cameron Baker, Francisco Chaves, Yi Zhang, Philip Rock, Richard Burack, John Ashton, Jane Liesveld, Jeevisha Bajaj

Blood (2025) 146 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2025-3186

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong, Pengxiang Guo, Lihong Shou, Hu Zhu, Zongjiu Jiao, Feng Zhang, Qingchi Liu, Lidong Zhao, Guocai Wu, Lili Chen, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2025-5530

Published: 2025

Journal Articles

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Blood (2025) 146 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2025-5584

Published: 2025

Journal Articles

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

Xin Huang, Qingrong Huang, Ciril Abraham, Mimi Chen, Ying Wang, Yuanyuan Tian, Yongping Zhang, Gennaro Calendo, Jean-Pierre Issa, Yi Zhang

Blood (2025) 146 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2025-5901

Published: 2025

Journal Articles

Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis

Chunhua Song, Benjamin Kaffenberger, Chelsea Steiner, Dayong Wu, Yi Zhang, Xiaopei Huang, Yiping Yang

Blood (2025) 146 (Supplement 1): 583.

https://doi.org/10.1182/blood-2025-583

Published: 2025

Journal Articles

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Blood (2025) 146 (11): 1314–1330.

https://doi.org/10.1182/blood.2025028560

Published: 2025

Includes: Supplemental data

Journal Articles

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Ying WANG, Qingrong Huang, Ruqayyah sanders-Braggs, Yan Zhou, Robert Hooper, Yuanyuan Tian, Tatiana Kent, Richard Pomerantz, Gennaro Clando, Jean-Pierre Issa, Jonathan Soboloff, Yi Zhang

Blood (2024) 144 (Supplement 1): 4769.

https://doi.org/10.1182/blood-2024-212207

Published: 2024

Journal Articles

Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

Ciril Abraham, Wenbin Mo, Tien Bui, Mimi Chen, Yuanyuan Tian, Gennaro Clando, Morgan Chaunzwa, Ying WANG, Jozef Madzo, Jean-Pierre Issa, Yi Zhang

Blood (2024) 144 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2024-211530

Published: 2024

Journal Articles

Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Ying WANG, Alicia Huaze Li, Ruqayyah sanders-Braggs, Yan Zhou, Mimi Chen, Tien Bui, Hongfa Zhu, Nasheed Hossain, Jonathan Soboloff, John Elrod, Elizabeth O. Hexner, Yi Zhang

Blood (2024) 144 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2024-212312

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Apolipoproteins from the microenvironment promote aggressive myeloid leukemia progression

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only